Viridian Therapeutics, Inc.\DE (VRDN) Receivables - Other (2016 - 2025)

Viridian Therapeutics, Inc.\DE's (VRDN) quarterly Receivables - Other came in at $70.0 million in Q3 2025, up 14513.78% quarter-over-quarter from $479000.0 in Q3 2021.

Viridian Therapeutics, Inc.\DE (VRDN) Receivables - Other (2016 - 2025) Analysis & Trends

Viridian Therapeutics, Inc.\DE's Receivables - Other history runs 5 years deep, the most recent figure standing at $70.0 million for Q3 2025.

  • On a quarterly basis, Receivables - Other changed N/A year-over-year to $70.0 million in Q3 2025; TTM through Sep 2025 was $70.0 million, a N/A change from a year earlier, with the FY2017 full-year figure at $1.1 million, up 266.67% from the prior year.
  • Receivables - Other improved to $70.0 million in Q3 2025 per VRDN's latest filing, from $479000.0 in the prior quarter.
  • Across five years, Receivables - Other topped out at $70.0 million in Q3 2025 and bottomed at $479000.0 in Q3 2021.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Viridian Therapeutics, Inc.\DE 229.55 Mn 229.55 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2025 70.00 Mn
Sep 30, 2025 70.00 Mn
Sep 30, 2021 479,000.00
Sep 30, 2021 479,000.00
Mar 31, 2018 955,000.00
Mar 31, 2018 955,000.00
Dec 31, 2017 1.10 Mn
Dec 31, 2017 1.10 Mn
Sep 30, 2017 1.44 Mn
Sep 30, 2017 1.44 Mn
Jun 30, 2017 467,200.00
Jun 30, 2017 467,200.00
Dec 31, 2016 300,000.00
Dec 31, 2016 300,000.00